The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre

Ioannis P Giannousis1, George V Papatheodoridis, Melanie J Deutsch

  • 1Second Department of Internal Medicine, Athens University Medical School, Hipppokration General Hospital, Athens 115 27, Greece.

Insights

Chronic viral hepatitis remains the leading cause of liver disease in Greece, but its patterns are shifting. An increase in immigrant populations and intravenous drug users is influencing these epidemiological changes.

Area of Science:

  • Hepatology
  • Epidemiology
  • Public Health

Background:

  • Chronic liver diseases represent a significant health burden globally.
  • Understanding epidemiological shifts is crucial for effective public health strategies.
  • Hepatitis B (HBV), Hepatitis C (HCV), Alcoholic Liver Disease (ALD), and Nonalcoholic Fatty Liver Disease (NAFLD) are key chronic liver conditions.

Purpose of the Study:

  • To investigate the prevalence and recent epidemiological changes of major chronic liver diseases.
  • To analyze trends in HBV, HCV, ALD, and NAFLD at a Greek tertiary referral center.

Main Methods:

  • A retrospective analysis of 1080 adult patients with chronic liver disease.
  • Patients were seen at an outpatient liver clinic between 2002 and 2007.
  • The study population was divided into two periods: 2002-2004 (Period A) and 2005-2007 (Period B).

Main Results:

  • Chronic viral hepatitis (HBV/HCV) accounted for 86.1% of cases, with HCV alone at 44.9%.
  • A decrease in HBV cases was observed (44.0% to 37.8%), with immigrants comprising a growing proportion.
  • Hepatitis B e antigen-positive cases and HCV cases linked to intravenous drug use showed an increasing trend.

Conclusions:

  • Chronic viral hepatitis continues to dominate chronic liver disease in Greek tertiary centers.
  • Epidemiological patterns are evolving, influenced by immigration and intravenous drug use.
  • Targeted interventions may be needed to address these changing demographics.
Abstract

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...